Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
This antibody doublet is essentially the new SOC in met-urothelial cancer. The anti-PD1 and ADC combination is compelling in many ways and the survival outcomes compared to chemo were very significant. This combination is on NCCN, as well.